Moleculin Biotech Files 8-K with Exhibits
Ticker: MBRX · Form: 8-K · Filed: Sep 9, 2025 · CIK: 1659617
Sentiment: neutral
Topics: 8-K, financial-statements, exhibits
Related Tickers: MBRX
TL;DR
Moleculin Biotech (MBRX) filed an 8-K on Sept 9th, check exhibits for news.
AI Summary
Moleculin Biotech, Inc. filed an 8-K on September 9, 2025, reporting on events that occurred on the same date. The filing includes financial statements and exhibits, and is related to Regulation FD disclosures. The company is incorporated in Delaware and headquartered in Houston, Texas.
Why It Matters
This 8-K filing indicates that Moleculin Biotech, Inc. is providing updated information and exhibits to the SEC, which could contain material disclosures for investors.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for financial statements and exhibits, not indicating any immediate significant operational or financial changes.
Key Players & Entities
- Moleculin Biotech, Inc. (company) — Registrant
- September 9, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Houston, TX (location) — Principal Executive Offices
- 713-300-5160 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Moleculin Biotech, Inc.?
The primary purpose of this 8-K filing is to report on events occurring on September 9, 2025, including Regulation FD disclosures and the filing of financial statements and exhibits.
When was the report filed with the SEC?
The report was filed as of September 9, 2025.
Where is Moleculin Biotech, Inc. headquartered?
Moleculin Biotech, Inc. is headquartered at 5300 Memorial Drive, Suite 950, Houston, TX 77007.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the registrant's telephone number?
The registrant's telephone number is (713) 300-5160.
Filing Stats: 595 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-09-09 08:45:10
Filing Documents
- mbrx20250908c_8k.htm (8-K) — 26KB
- ex_859893.htm (EX-99.1) — 20KB
- logobig.jpg (GRAPHIC) — 19KB
- 0001437749-25-028604.txt ( ) — 234KB
- mbrx-20250909.xsd (EX-101.SCH) — 3KB
- mbrx-20250909_def.xml (EX-101.DEF) — 12KB
- mbrx-20250909_lab.xml (EX-101.LAB) — 15KB
- mbrx-20250909_pre.xml (EX-101.PRE) — 12KB
- mbrx20250908c_8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure On September 9, 2025, Moleculin Biotech, Inc. (the "Company"), issued a press release which announced updates to its active site status and recruitment for its pivotal Phase 2B/3, multi-center, randomized, double-blind, placebo-controlled, adaptive design study of Annamycin in combination with cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is referred to as "AnnAraC") for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy (R/R AML). This Phase 3 "MIRACLE" trial (derived from Moleculin R/R AML AnnAraC Clinical Evaluation) is a global approval trial, including sites in the US, Europe and the Middle East. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended ("Securities Act"), unless specifically identified therein as being incorporated by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated September 9, 2025 104 Cover page Interactive Data File (formatted as Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MOLECULIN BIOTECH, INC. Date: September 9, 2025 By: /s/ Jonathan P. Foster Jonathan P. Foster